We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MicroRNA-Based Diagnostic to Predict Lung Cancer Recurrence

By Labmedica staff writers
Posted on 18 Jun 2008
A microRNA-based diagnostic test will be developed to predict risk of disease recurrence in lung cancer patients who have undergone curative resection.

MicroRNAs (miRNAs) are naturally occurring, small RNAs that have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs promises to provide the means to treat a wide range of human diseases. MicroRNAs have been shown to have different expression in various pathologic conditions; these differences should provide for a novel diagnostic strategy for many diseases.

Current treatment for lung cancer includes surgical resection that may be followed by adjuvant therapy. Patients with high risk of recurrence might benefit from adjuvant therapy, but those with low risk of recurrence could be exposed to unnecessary toxicities.

Rosetta Genomics, Ltd. (Rehovot, Israel) will collaborate with the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA) and the University's Kleberg Center for Molecular Markers to develop a test that will enable physicians to distinguish between patients with high- and low-risk of recurrence to optimize treatment regimens.

Lung cancer is the leading cause of cancer death among both men and women worldwide and in the United States. In 2008 alone, there will be about 215,020 new cases of lung cancer in the United States, and approximately 160,000 people are expected to die of the disease.

"The potential diagnostic applications of microRNA biomarkers are broad and diverse,” noted Mr. Amir Avniel, president and CEO of Rosetta Genomics. "We are very pleased to be collaborating with M.D. Anderson, one of the world's leading cancer research centers, on this important project in lung cancer. We believe that the experience we have in working with microRNA biomarkers, combined with M.D. Anderson's extensive experience in lung cancer research, makes this a strong collaboration which may have a significant impact on the way lung cancer patients are diagnosed and treated.


Related Links:
Rosetta Genomics
The University of Texas M.D. Anderson Cancer Center

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Candida Glabrata Test
ELIchrom Glabrata

Latest Molecular Diagnostics News

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
18 Jun 2008  |   Molecular Diagnostics

New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
18 Jun 2008  |   Molecular Diagnostics

Injury Molecular Fingerprint Enables Real-Time Diagnostics for On-Site Treatment
18 Jun 2008  |   Molecular Diagnostics



PURITAN MEDICAL